Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.

Suzuki J, Yamakawa T, Oba M, Nagakura J, Shigematsu E, Tamura H, Takahashi K, Okamoto Y, Sakamoto R, Shinoda M, Takano T, Kadonosono K, Terauchi Y.

Endocr J. 2019 Jul 4. doi: 10.1507/endocrj.EJ18-0309. [Epub ahead of print]

2.

Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.

Onda Y, Nishimura R, Ando K, Takahashi H, Tsujino D, Utsunomiya K.

Diabetes Res Clin Pract. 2016 Oct;120:149-55. doi: 10.1016/j.diabres.2016.07.019. Epub 2016 Aug 6.

PMID:
27562434
3.

Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).

Miura H, Sakaguchi K, Okada Y, Otowa-Suematsu N, Yamada T, So A, Komada H, Hirota Y, Kishi M, Takeda A, Tominaga Y, Nakamura T, Kuroki Y, Matsuda T, Iida K, Kajikawa M, Ohara T, Yokota K, Hara K, Tateya S, Tamori Y, Ogawa W.

Diabetes Ther. 2018 Dec;9(6):2399-2406. doi: 10.1007/s13300-018-0523-0. Epub 2018 Oct 19.

4.

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.

Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P.

JAMA. 2017 Jul 4;318(1):45-56. doi: 10.1001/jama.2017.7117.

5.

Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.

Heise T, Kaplan K, Haahr HL.

J Diabetes Sci Technol. 2018 Mar;12(2):356-363. doi: 10.1177/1932296817731422. Epub 2017 Sep 26.

6.

Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.

Iga R, Uchino H, Kanazawa K, Usui S, Miyagi M, Kumashiro N, Yoshino H, Ando Y, Hirose T.

Diabetes Ther. 2017 Aug;8(4):783-792. doi: 10.1007/s13300-017-0269-0. Epub 2017 May 25.

7.

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.

Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1.

JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115.

8.

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.

Evans M, Chubb B, Gundgaard J.

Diabetes Ther. 2017 Apr;8(2):275-291. doi: 10.1007/s13300-017-0236-9. Epub 2017 Feb 16.

9.

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.

Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators.

Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22.

10.

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.

Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S.

Diabetes Obes Metab. 2017 Nov;19(11):1562-1569. doi: 10.1111/dom.12972. Epub 2017 Jul 10.

11.

The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial.

Iuchi H, Sakamoto M, Matsutani D, Suzuki H, Horiuchi R, Utsunomiya K.

Diabetes Technol Ther. 2017 Aug;19(8):457-462. doi: 10.1089/dia.2017.0028. Epub 2017 Jun 12.

PMID:
28605286
12.

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group.

Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30.

13.

Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.

Aso Y, Suzuki K, Chiba Y, Sato M, Fujita N, Takada Y, Murano S, Kuroda H.

Diabetes Res Clin Pract. 2017 Aug;130:237-243. doi: 10.1016/j.diabres.2017.06.007. Epub 2017 Jun 15.

PMID:
28651211
15.

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.

Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R.

Drugs R D. 2016 Jun;16(2):239-49. doi: 10.1007/s40268-016-0134-z.

16.

Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.

Nakamura T, Sakaguchi K, So A, Nakajima S, Takabe M, Komada H, Okuno Y, Hirota Y, Nakamura T, Iida K, Kajikawa M, Nagata M, Ogawa W, Seino S.

Diabetologia. 2015 Sep;58(9):2013-9. doi: 10.1007/s00125-015-3648-y. Epub 2015 Jun 5.

17.

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.

Evans M, Mehta R, Gundgaard J, Chubb B.

Diabetes Ther. 2018 Oct;9(5):1919-1930. doi: 10.1007/s13300-018-0478-1. Epub 2018 Aug 10.

18.

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R; NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators.

Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31. doi: 10.1016/S2213-8587(13)70013-5. Epub 2013 Jul 9.

PMID:
24622318
19.

Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.

Gilor C, Culp W, Ghandi S, do Carmo Emidio E Silva JA, Ladhar A, Hulsebosch S.

Domest Anim Endocrinol. 2019 Oct;69:19-29. doi: 10.1016/j.domaniend.2019.04.001. Epub 2019 Apr 16.

PMID:
31280022
20.

Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.

Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y.

Endocr Pract. 2014 Apr;20(4):285-92. doi: 10.4158/EP13287.OR.

PMID:
24246344

Supplemental Content

Support Center